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Abstract
 
Sequence-independent interactions involving the free peptidic NH
 
2
 
 terminus are thought to be
an essential feature of peptide binding to classical major histocompatibility complex (MHC)
 
class I proteins. Challenging this paradigm, a natural 
 
N
 
a
 
-acetylated ligand of human histocom-
patibility leukocyte antigen (HLA)-B39 was identified in this study. It matched the NH
 
2
 
-ter-
minal sequence of two human helicases, was resistant to aminopeptidase M, and was produced
with high yield from a synthetic 30 mer with the sequence of the putative parental protein by
the 20S proteasome. This is the first reported natural ligand of classical MHC class I antigens
that has a blocked NH
 
2
 
 terminus.
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Introduction
 
Classical MHC class I molecules (HLA-A,B,C in humans)
constitutively bind peptides from endogenously synthesized
cell proteins and from intracellular pathogens, and present
 
them at the cell surface for recognition by CD8
 
1
 
 CTLs.
Peptides bind the class I molecule in its peptide binding
site. This is a groove formed by the 
 
a
 
1 and 
 
a
 
2 domains of
the heavy chain, consisting of two long 
 
a
 
-helical segments
on top of an eight-strand antiparallel 
 
b
 
-pleated sheet (1, 2).
The fine structure of this groove can be described as a series
of subsites (pockets A–F) formed by side chains of residues
from the MHC molecule (3, 4). Peptides bind to class I
molecules in extended conformation, with the NH
 
2 
 
and
COOH termini interacting in pockets A and F, respec-
tively, and various peptidic anchor residues interacting in
the other pockets (5). MHC polymorphism occurs mainly
in the peptide binding groove and, by affecting the size,
shape, and polarity of the pockets, modulates the peptide
binding specificity of class I molecules.
A major feature of the peptide binding groove of classical
class I antigens, which distinguishes it from class II mole-
cules, is that the two 
 
a
 
-helical segments come close to each
other at both ends. In addition, the ends of the groove be-
come blocked by bulky side chains including Tyr84
(pocket F) and Trp167 (pocket A), which are highly con-
served among class I proteins. This imposes strong restric-
tions on the size of class I–bound peptides, so that these
have a size range of 8–12 residues, with a majority of non-
amers (6). Size variations are usually accommodated by dif-
ferential bulging or other conformational changes in the
middle part of the peptide (7–9). The peptidic NH
 
2 
 
and
COOH termini bind the class I molecule through hydro-
gen bonds to conserved residues in pockets A and F, re-
spectively, essentially in a peptide sequence–independent
mode. These interactions have a significant contribution to
the total binding energy of the peptide (10, 11). Neverthe-
less, class I ligands can also bind with the COOH-terminal
residue positioned outside the peptide binding groove, and
this noncanonical binding mode is stable at physiological
temperature (12).
In contrast, it is currently assumed that there is a univer-
sal binding mode for peptidic NH
 
2
 
 termini. All known nat-
ural ligands of classical class I antigens have a free NH
 
2
 
 ter-
minus. This interacts in the A pocket through a set of
hydrogen bonds established directly with Tyr7 and Tyr171,
and with Tyr59 through a water molecule (5, 13). Suppres-
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sion of these hydrogen bonds by NH
 
2
 
-terminal methyla-
tion of a peptide ligand of HLA-A2 decreased the thermal
stability of the peptide–MHC complex by 22
 
8
 
C, indicating
that the NH
 
2
 
 terminus is an energetically important site for
class I binding (10). 
 
N
 
a
 
-acetylation has been shown to sig-
nificantly decrease binding of peptide ligands to classical
MHC class I proteins (14, 15). In contrast, the nonclassical
murine antigen H2-M3 specifically binds 
 
N
 
-formylated
peptides (16–18). This is made possible through various
amino acid changes in the protein molecule, including
some that dramatically affect the structure of pocket A
(19, 20).
The apparent inability of class I antigens to bind 
 
N
 
a
 
-
acetylated ligands is in contrast with the relatively frequent
occurrence of 
 
N
 
a
 
-acetylated proteins in eucariotic cells
(21, 22). We report here that an 
 
N
 
a
 
-acetylated peptide is a
natural ligand of HLA-B39. This is, to our knowledge, the
first known 
 
N
 
-acetylated ligand of any class I molecule, and
the first natural ligand with a blocked NH
 
2
 
 terminus re-
ported from a classical MHC class I protein. In addition,
we show that this peptide is directly generated by the 20S
proteasome as a major breakdown product of a precursor
substrate with the sequence of the corresponding parental
protein.
 
Materials and Methods
 
HLA-B39 Transfectant Cell Lines. 
 
HMy2.C1R (C1R)
 
1
 
 is a
human lymphoid cell line with low expression of its endogenous
class I antigens. C1R transfectants expressing B
 
*
 
3901 or B
 
*
 
3909
have been described previously (23). The B
 
*
 
3905-C1R transfec-
tant was obtained with the same electroporation and selection
procedures as the previous transfectants, using a full-length
cDNA clone with the coding B
 
*
 
3905 sequence (a gift from Dr.
Peter Parham, Stanford University, Stanford, CA) subcloned into
the RSV5
 
neo
 
 vector. HLA-B39–C1R transfectant cells were cul-
tured in DMEM supplemented with 7.5% heat-inactivated FCS
(both from GIBCO BRL). RMA-S is a transporter associated
with antigen processing–deficient murine cell line (24, 25). The
B
 
*
 
3909–RMA-S (23) and B
 
*
 
2705–RMA-S (26) cells used in this
study, which also express human 
 
b
 
2-microglobulin, have been
described elsewhere. These cells were grown in RPMI 1640 me-
dium containing 25 mM Hepes buffer and 5% heat-inactivated
FCS (GIBCO BRL).
 
Isolation of HLA-B39–bound Peptides. 
 
This was carried out as
described previously (27). In brief, 
 
z
 
10
 
10
 
 cells were grown at
37
 
8
 
C in DMEM, pH 7.4 containing 7.5% heat-inactivated FCS,
100 
 
m
 
g/ml streptomycin sulfate, and 100 U/ml penicillin G (all
from GIBCO BRL). Cells were lysed in 1% NP-40 in the pres-
ence of a cocktail of protease inhibitors, and B
 
*
 
3901, B
 
*
 
3905, or
B
 
*
 
3909 were purified by affinity chromatography from the cell
lysates using the W6/32 mAb (IgG2a, specific for a monomor-
phic HLA-A,B,C determinant; reference 28). HLA-B39–bound
peptide pools were obtained by acid extraction with 0.1% TFA,
and were fractionated by HPLC.
 
Mass Spectrometry Analysis and Sequencing. 
 
The peptide com-
position of HPLC fractions or other samples was analyzed by ma-
trix-assisted desorption ionization time-of-flight (MALDI-TOF)
mass spectrometry (MS) using a calibrated Kompact Probe instru-
ment (Kratos-Schimadzu) operating in the positive linear mode,
as described previously (27). Peptide composition analysis, zoom-
scan, and sequencing by electrospray ion trap MS was carried out
with an LCQ instrument (Finnigan ThermoQuest) and using the
“nanospray” interface, as detailed elsewhere (23, 29). Zoomscan
is a high-resolution method for determining accurate peptide
mass and charge of ionic species, in which a precursor ion win-
dow is selected to incorporate several isotopomers. The charge
states of individual product ions were determined at enhanced
resolution by scanning across a limited m/z range.
 
Synthetic Peptides.
 
Peptides were synthesized using the stan-
dard solid-phase Fmoc chemistry, and were purified by HPLC.
In the case of 
 
N
 
-acetyl (NAc) peptides, acetylation was carried
out manually as follows: some of the peptide resin was treated to
remove the Fmoc group without removing the side chain pro-
tecting groups, then was incubated with an excess of an acetyla-
tion cocktail containing 10% acetic anhydride in 
 
N
 
-methyl-pyr-
rolidone-2 (SDS; Peypin) and shaken for 10 min. The filtered
peptide resin was then washed eight times with dichloromethane
(SDS; Peypin) before removing the protecting groups of the pep-
tide side chains. The correct composition and molecular mass of
purified peptides were confirmed by amino acid analysis using a
6300 amino acid analyzer (Beckman Coulter), which also al-
lowed their quantification, and by electrospray ion trap MS, re-
spectively.
 
Digestions with Aminopeptidase M. 
 
Approximately 70% of the
HPLC fraction containing the NAc-SHVAVENAL peptide from
the B
 
*
 
3905-bound peptide pool was dried down, resuspended in
5 
 
m
 
l of methanol/water (1:1 vol/vol) containing 0.1% formic
acid, and sonicated for 5 min. A 2-
 
m
 
l aliquot of this mixture (28%
of the fraction) was used for MALDI-TOF MS analysis. Another
2-
 
m
 
l aliquot of the same mixture was digested as follows: 0.5 
 
m
 
l
of a suspension containing 10
 
2
 
2
 
 U of aminopeptidase M from pig
kidney (Boehringer), 0.5 
 
m
 
l 100 mM Tris, and 2 
 
m
 
l H
 
2
 
O was
added in an eppendorf tube and incubated for 10 min at 37
 
8
 
C.
The digestion was stopped by adding 0.2 
 
m
 
l of TFA. This whole
mixture was then subjected to MALDI-TOF MS analysis.
 
Epitope Stabilization Assay and Flow Microfluorometry Analysis.
 
The epitope stabilization assay used to measure peptide binding
was performed as described (23). In brief, B
 
*
 
3909–RMA-S or
B
 
*
 
2705–RMA-S
 
 
 
transfectants were incubated at 26
 
8
 
C for 24 h.
They were then incubated for 1 h at 26
 
8
 
C with 10
 
2
 
4
 
 –10
 
2
 
9
 
 M
peptide without FCS, transferred to 37
 
8
 
C, and collected for flow
microfluorometry after 4 h. B
 
*
 
3909 or B
 
*
 
2705 expression was
measured using 50 
 
m
 
l of hybridoma culture supernatant contain-
ing the mAb W6/32 (28; for B
 
*
 
3909) or ME1 (30; for B
 
*
 
2705),
as described previously (31). Binding was expressed as the C50,
which is the molar concentration of any given peptide at 50% of
the maximum fluorescence obtained at the concentration range
used. Binding of acetylated
 
 
 
peptides was assessed as the concen-
tration of the acetylated
 
 
 
peptide required to obtain the fluores-
cence value at C50 of the corresponding unblocked
 
 
 
peptide. This
was designated as EC50. Relative binding was calculated as the
ratio between the C50 of the unblocked peptide and the EC50 of
the corresponding 
 
N
 
a
 
-acetylated analogue.
 
Purification of 20S Proteasome.
 
Approximately 3 
 
3 
 
10
 
9
 
 B
 
*
 
2705-
C1R cells were potter lysed in 50 ml of 50 mM Tris/HCl and 25
mM KCl, pH 8. The homogenate was centrifuged at 1,500 
 
g
 
 for
10 min. The supernatant was further centrifuged at 100,000 
 
g
 
 for
 
1
 
Abbreviations used in this paper: 
 
C1R, HMy2.C1R; MALDI-TOF, ma-
trix-assisted laser desorption ionization time-of-flight; MS, mass spec-
trometry; NAc, 
 
N
 
-acetyl. 
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1 h and fractionated on a 35-ml DEAE-cellulose DE52 column
(Whatman) equilibrated in homogenization buffer. Proteins were
eluted with 0.3 M KCl in 50 mM Tris/HCl buffer and concen-
trated in an 8-ml DEAE-cellulose DE52 column equilibrated in
homogenization buffer. Bound proteins were eluted with 50 mM
Tris/HCl and 0.3 M KCl, pH 8. Protein-containing fractions
were scanned using the Bradford method (Bio-Rad) and further
subjected to centrifugation at 200,000 
 
g
 
 for 18 h in a gradient of
10–30% glycerol in 1 M urea, 50 mM Tris/HCl, and 50 mM
KCl, pH 8. Proteasome-containing fractions were identified by
12% SDS-PAGE and further subjected to anion-exchange chro-
matography in a MonoQ SR5/5 column (Amersham Pharmacia
Biotech) at a flow rate of 0.5 ml/min, as follows: isocratic condi-
tions with buffer A (50 mM Tris/HCl, 50 mM KCl, pH 8) for 10
min, followed by a linear gradient of 0–30% buffer B (50 mM
Tris/HCl, 0.5 M KCl, pH 8) for 5 min and a linear gradient of
30–100% buffer B for another 30 min. Purity of the fractions was
assessed by denaturing SDS-PAGE as above. Aliquots of purified
proteasome were stored at 
 
2
 
70
 
8
 
C.
 
Proteasome Digestion.
 
This was performed at 37
 
8
 
C in 20 mM
Hepes buffer, pH 7.4 at a ratio of 83.3 ng of peptide substrate to
8.3 ng of proteasome per 
 
m
 
l. Approximately 10 
 
m
 
g of peptide
was digested at 4, 8, and 24 h. 1 vol of 0.1% aqueous TFA was
added to stop the enzyme reaction. Digestion mixtures were frac-
tionated by HPLC using a 2.1 
 
3 
 
250 mm C18 (5 mm) column
(Vydac) at a flow rate of 100 ml/min with the following chro-
matographic gradient: isocratic conditions with buffer A (0.08%
TFA in water) for 15 min followed by a linear gradient of 0–44%
buffer B (80% acetonitrile, 0.075% TFA in water) for 90 min, and
a linear gradient of 44–100% buffer B for 35 min. Peptide frac-
tionation was simultaneously monitored at 210 nm and 280 nm
using a Waters 991 photodiode array detector. Fractions of 50 ml
were collected and stored at 2208C.
The yield of individual digestion products was estimated as fol-
lows. For those peptides eluting as the single molecular species in
an HPLC peak, their yield was expressed as the percentage of the
absorbance peak area at 210 nm, relative to the total area of the
peaks corresponding to digested material. For peptides coeluting
in a same HPLC peak, the proportion of each peptide in the mix-
ture was estimated on the basis of their respective intensity signals
in the MALDI-TOF spectra. This method provides only an ap-
proximate estimation of peptide yields, as peptides with different
length have different absorbance at 210 nm, and the MALDI-
TOF signals of coeluting peptides may not correlate strictly with
peptide concentration. However, it allows the distinguishing of
major from minor digestion products.
Results
MS Analysis of HLA-B39–bound Peptides Reveals a Puta-
tive Na-acetylated Ligand. B*3901-, B*3909-, and B*3905-
bound peptides were extracted from the corresponding im-
munopurified HLA molecules expressed on C1R trans-
fectants and fractionated by HPLC. Full-scan analysis by
nanoelectrospray ion trap MS of HPLC fraction number
(N.) 155 from B*3901 (Fig. 1 A) revealed various ion
peaks. Among these, those at m/z 848.4 and 870.4 were
compatible with a peptide (M91H1) and its Na1 adduct,
respectively. MS/MS fragmentation analysis of the former
ion allowed us to determine its amino acid sequence as
THGPPVQL (23). A second peptide was revealed by ion
peaks at m/z 981.4 (M1H1), 502.4 (presumably M1H11
Na1), and 510.5 (presumably M1H11K1). A peptide
with the same mass was also detected in the correspond-
ing HPLC fractions from B*3909 and B*3905 (Fig. 1, B
and C).
Zoomscan analysis of the ion peak at m/z 981.4 from
B*3901 and the corresponding ones from B*3909 and
B*3905 yielded a monoisotopic peptide mass of 980.4–
980.5 (Fig. 1 C). MS/MS fragmentation analysis of this ion
peak from B*3901 yielded a daughter spectrum (Fig. 2 A)
that was consistent with the sequence XHVAVENAL. Al-
though residue X had a molecular mass corresponding to
that of glutamic acid (E), no match with any peptide was
Figure 1. Presence of a common ligand in three HLA-B39 subtypes.
(A)  Full-scan MS spectrum of HPLC fraction N. 155 of the HLA-
B*3901–bound peptide pool. Ion peaks at m/z 502.4 and 510.5 can be
related to the ion peak at m/z 981.4 as Na1 and K1 adducts, respectively.
Ion peaks at m/z 848.4 and 870.4 correspond to THGPPVQL (reference
23) and its Na1 adduct. (B) Full-scan MS spectrum of HPLC fraction N.
155 of the B*3909-bound peptide pool, containing the molecular species
with m/z 981.5. Ion peaks related to this peptide are indicated. (C)
Zoomscan spectrum of the ion peak at m/z 981.4 from HPLC fractions
N. 155 of the B*3901- (left), B*3909- (middle), and B*3905-bound
(right) peptide pools. The difference of 1Da observed among the various
isotopomers of the precursor ion (M1H1) is consistent with a monoiso-
topic mass (M) of 980.4–980.5.2086 An Na-acetylated Ligand of Class Ia HLA Antigens
found when the MS/MS spectrum was used to search
against the nr.fasta protein database. In addition, no peptide
with the sequence EHVAVENAL was found upon scan-
ning of multiple protein or nucleotide databases. However,
a sequence SHVAVENAL was found, which was identical
except for the NH2-terminal residue. It corresponded to
the NH2-terminal sequence of the human protein RNA
helicases of the DEAD box family DBX (32) and CAP-Rf
(33). The mass difference between the E and S residues (42
Da) was consistent with an acetyl group. Because NH2-ter-
minal acetylation is a common posttranslational modifica-
tion, our results raised the possibility that XHVAVENAL
was an Na-acetylated ligand of B*3901. Identical results
were obtained from the MS/MS analyses of the corre-
sponding ion peaks from B*3909 and B*3905 (data not
shown), indicating that the same peptide was present in the
three HLA-B39 subtypes.
To confirm the sequence assignment, synthetic EH-
VAVENAL and NAc-SHVAVENAL peptides were sepa-
rately subjected to MS/MS fragmentation analysis. Whereas
the daughter spectrum of NAc-SHVAVENAL (Fig. 2 B)
was identical to that of XHVAVENAL, the MS/MS spec-
trum of EHVAVENAL yielded an additional set of ion
peaks corresponding to the b0 series, generated from neutral
loss of water from ions of the b series (Fig. 2 C). This dif-
ference between the two peptides was consistently found at
various peptide concentrations, ionization conditions, or
collision energies (data not shown). Taken together, these
results strongly suggest that B*3901, B*3909, and B*3905
bind a natural Na-acetylated ligand derived from the NH2-
terminal region of human proteins.
The Natural HLA-B39 Ligand Has the Same Retention
Time as NAc-SHVAVENAL in HPLC. In a further anal-
ysis, we compared the HPLC retention times of the natural
B*3901 ligand XHVAVENAL and the synthetic peptides
NAc-SHVAVENAL and EHVAVENAL. The THGP-
PVQL peptide, which coeluted with XHVAVENAL in the
HPLC fractionation of B*3901-bound peptides (Fig. 1 A),
was used as a marker for the retention time of XHVAVE-
NAL. Thus, similar amounts of the synthetic EHVAVE-
NAL, NAc-SHVAVENAL, and THGPPVQL peptides
were separately subjected to HPLC under identical condi-
tions in consecutive runs (Fig. 2 D). The two latter pep-
tides showed almost identical retention times, whereas EH-
VAVENAL eluted significantly earlier. The same result was
obtained when the three peptides were mixed together and
Figure 2. Evidence for an
Na-acetylated ligand of HLA-
B39. (A) MS/MS spectrum of
the ion peak at m/z 981.3 from
HPLC fraction N. 155 of the
B*3901-bound peptide pool.
The assigned peptide sequence is
indicated, detailing the observed
backbone fragment ions accord-
ing to a standard nomenclature
(reference 49). The precursor ion
(M1H1) and related ions result-
ing from neutral loss of water or
ammonia are indicated. This se-
quence is compatible with X be-
ing Glu or NAc-Ser, but no
other unmodified amino acid res-
idue. (B) MS/MS spectrum of
the synthetic peptide NAc-SH-
VAVENAL. Conventions are as
in A. (C) MS/MS spectrum of
the synthetic peptide EHVAVE-
NAL. In addition to fragment
ions of the b and y99 series, those
corresponding to the b0 series are
indicated. This is generated by
neutral loss of water from ions of
the b series. (D) HPLC chroma-
tography of the synthetic pep-
tides EHVAVENAL, NAc-SH-
VAVENAL, and THGPPVQL.
This latter peptide is a natural
B*3901 ligand that coelutes with
XHVAVENAL in the HPLC
fractionation of B*3901-bound
peptides (shown in Fig. 1 A).
The three peptides were sepa-
rately chromatographed under
identical conditions in consecu-
tive runs, and the chromatograms
are superimposed.2087 Yagüe et al.
fractionated in a single HPLC run (data not shown). This
result confirms that the natural ligand with M1H1 981.4
coeluting with THGPPVQL in the HPLC fractionation of
the B*3901-bound peptide pool is NAc-SHVAVENAL.
The Natural HLA-B39 Ligand Is Resistant to Digestion by
Aminopeptidase M.  The HPLC fraction from B*3905-
bound peptides containing the putatively Na-acetylated
ligand showed a complex composition when analyzed by
MALDI-TOF MS (Fig. 3 A). Among the peptides present,
those at m/z 848.3 and 981.4 were shown by MS/MS frag-
mentation analysis to be THGPPVQL and XHVAVE-
NAL, respectively. An aliquot of this HPLC fraction iden-
tical to that used for MALDI-TOF analysis (z30% of the
total) was digested with aminopeptidase M, an enzyme
known to hydrolyze peptide bonds from small peptides
with free, but not blocked, NH2 termini (34, 35). When
the digestion mixture was analyzed by MALDI-TOF MS,
most peak signals in the undigested aliquot were reduced to
background levels, whereas the peaks corresponding to
XHVAVENAL (m/z: 982.0) and its Na1 adduct (m/z:
1004.2) remained as the only significant signals above back-
ground. As a control for this digestion, an approximately
equimolar mixture of the synthetic peptides THGPPVQL
and NAc-SHVAVENAL was treated with aminopeptidase
M under the same conditions, and the mixture was ana-
lyzed by MALDI-TOF MS before and after digestion (Fig.
3, C and D). Whereas the peak signal of the former peptide
(m/z: 849.1) was reduced almost to background levels after
digestion, the signals corresponding to NAc-SHVAVE-
NAL (m/z: 982.2 and 1004.1) remained strongly signifi-
cant. These results indicate that XHVAVENAL has a
blocked NH2 terminus, further confirming the assigned
NAc-SHVAVENAL sequence.
NAc-SHVAVENAL Is Generated with High Yield by the
20S Proteasome.  An Na-acetylated synthetic 30 mer with
the NH2-terminal sequence of the putative parental pro-
teins of NAc-SHVAVENAL and the DBX and CAP-Rf
helicases (32, 33) was digested in vitro with purified 20S
proteasome for 4, 8, and 24 h, and the digestion mixtures
were separately fractionated by HPLC. Approximately 26,
39, and 63% of the 30 mer, respectively, was digested at
each of the three time points.
All HPLC fractions from the 24-h digest eluting be-
tween 50 and 120 min, which encompasses virtually all
eluted peptides (Fig. 4 A), were analyzed by MALDI-TOF
MS. In addition, those HPLC fractions corresponding to
peptide peaks were also analyzed by electrospray ion trap
MS to detect possible additional peptides not seen by
MALDI-TOF and to unambiguously characterize some of
the digestion products through MS/MS sequencing. This
analysis allowed us to determine the digestion pattern of
the 30 mer, and revealed the presence of NAc-SHVAVE-
NAL (1–9) as the main component of one of the major
peptide peaks (Fig. 4 A).
As shown in Fig. 4 B, the NAc-SHVAVENAL peptide
was directly generated by the 20S proteasome with high
yield, accounting for z16% of the total digest. This was due
to a highly efficient cleavage at the L9-G10 peptide bond of
the Na-acetylated precursor and to absence of any significant
cleavage at peptide bonds between amino acids S1 to L9. 
NAc-SHVAVENAL Binds HLA-B39 In Vitro with De-
creased Efficiency.  Because the peptidic NH2 terminus
Figure 3. A blocked NH2 ter-
minus of XHVAVENAL is
revealed by resistance to ami-
nopeptidase M. (A)  MALDI-
TOF MS spectrum of HPLC
fraction N. 155 of B*3905-
bound peptides. Peaks corre-
sponding to XHVAVENAL (m/z:
981.4), Na1 and K1 adducts, and
THGPPVQL (m/z: 848.3) are
indicated. (B) MALDI-TOF MS
spectrum of the same HPLC
fraction as in A after digestion
with 0.01 U of aminopeptidase
M for 10 min at 378C. The only
major peaks are those corre-
sponding to XHVAVENAL (m/z:
982.0) and its Na1 adduct (m/z:
1004.2). (C)  MALDI-TOF MS
spectrum of a mixture of the syn-
thetic peptides THGPPVQL
(m/z: 848.6) and NAc-SH-
VAVENAL (m/z: 981.6). (D)
MALDI-TOF MS spectrum of
the same mixture as in C di-
gested with 0.01 U of aminopep-
tidase M for 10 min at 378C.2088 An Na-acetylated Ligand of Class Ia HLA Antigens
plays a significant role in peptide anchoring to the class I
molecule (10), we analyzed the effect of Na-acetylation on
binding to B*3909 in vitro using an epitope stabilization as-
say. The synthetic peptides SHVAVENAL and NAc-SH-
VAVENAL, as well as two unrelated natural ligands of
B*3909 (ARDETEFYL and YRPGTVAL; reference 23),
were tested (Fig. 5 A). Although SHVAVENAL bound to
B*3909 similarly as the two natural ligands with free NH2
terminus, NAc-SHVAVENAL bound z10-fold less effi-
ciently than the nonacetylated analogue (relative binding
1:11). These results indicate that Na-acetylation of a Ser
residue decreases but does not abrogate binding to B*3909
in vitro.
Limited Influence of P1 Variability on Binding of Na-acety-
lated Peptides. Molecular modeling suggested a binding
mode for NAc-SHVAVENAL in which the Ser1 side
chain was switched towards the A pocket in order to lo-
cate the acetyl group towards the solvent (data not
shown). In this model, hydrogen bonding through the
b-hydroxyl group of Ser1 would partially compensate for
loss of the canonic interactions involving the peptidic NH2
terminus.
Figure 4. The NAc-SHVAVENAL peptide is produced with high
yield by the 20S proteasome. (A) HPLC fractionation of the proteasomal
digestion products from an Na-acetylated synthetic 30 mer with the se-
quence of the putative parental protein of NAc-SHVAVENAL. Approx-
imately 10 mg of substrate was digested with purified 20S proteasome for
24 h at an enzyme/substrate weight ratio of 1:10 as described in Materials
and Methods. The peak corresponding to undigested substrate and its
amino acid sequence are indicated. The peptides found in HPLC peaks
upon MALDI-TOF MS analysis of the corresponding fractions are indi-
cated by the residue numbers of the precursor substrate. (B) Cleavage
pattern of the 24-h digestion of the 30-mer substrate by the 20S protea-
some. Peptides detected in the digestion mixture are shown as bold lines.
Small, medium, and large arrows indicate cleavage sites that generated
peptides with total yields of ,5%, 5–10%, and .10%, respectively, rela-
tive to the total digest. Peptide yields were estimated as described in Ma-
terials and Methods.
Figure 5. Limited influence of P1 side chain variability on binding of
N-acetylated peptides. Epitope stabilization assay showing the expression
of B*3909 on the surface of RMA-S transfectant cells. B*3909-associated
fluorescence at various peptide concentrations was measured with the
W6/32 mAb (described in Materials and Methods). Data are means 6 SD
of three independent experiments. (A) Binding of SHVAVENAL (C50: 8
mM) and NAc-SHVAVENAL (EC50: 90 mM; relative binding 1:11).
ARDETEFYL (C50: 5 mM) and YRPGTVAL (C50: 12 mM) are natural
ligands of B*3909 (23). GRIDKPILK is a natural ligand of HLA-B27
(reference 50) used as negative control. (B) Binding of THVAVENAL
(C50: 11 mM) and NAc-THVAVENAL (EC50: 68 mM; relative binding
1:6). (C) Binding of AHVAVENAL (C50: 8 mM) and Nac-AHVAVE-
NAL (EC50: 48 mM; relative binding 1:6). (D) Binding of FHVAVE-
NAL (C50: 2 mM) and NAc-FHVAVENAL (EC50: 38 mM; relative
binding 1:19).2089 Yagüe et al.
To test this model, we reasoned that variations in the size
and/or polarity of the P1 side chain should significantly af-
fect binding of the corresponding N-acetylated analogues.
In contrast, if the binding mode of the N-acetylated ligand
does not involve reorientation of the P1 side chain towards
pocket A, the effect of N-acetylation should be less depen-
dent on the P1 residue.
Thus, synthetic THVAVENAL, AHVAVENAL, and
their Na-acetylated analogues were tested for binding to
B*3909 in vitro (Fig. 5, B and C). The Na-acetylated pep-
tides bound B*3909 with similarly decreased efficiency rel-
ative to their nonacetylated counterparts (relative binding
1:6 in both cases) as NAc-SHVAVENAL. These results in-
dicate that neither a moderately increased size (Thr) nor re-
moval of the hydroxyl group (Ala) had a significant effect
on binding of the corresponding Na-acetylated peptides.
However, it could be argued that Na-acetylation of
small P1 residues might still be compatible with binding of
the P1 side chain in the A pocket. Thus, we tested the ef-
fect of Na-acetylation on binding of a peptide analogue
with the bulky and apolar Phe1, whose size precludes its
side chain from entering into the A pocket (Fig. 5 D).
Binding of NAc-FHVAVENAL relative to its unblocked
counterpart was somewhat lower than for other P1 residues
(1:19). However, its binding efficiency (EC50: 38 mM) was
similar to the other N-acetylated peptides tested (Fig. 5).
These results indicate that the size and polarity of the P1
residue have a limited influence on binding of Na-acety-
lated peptides in our epitope stabilization assay, and suggest
that their binding mode may not involve interaction of the
N-acetylated P1 side chain in the A pocket.
Similar Effect of Na-acetylation on Peptide Binding to HLA-
B27.  To test whether the effect of Na-acetylation ob-
served in HLA-B39 could be generalized to other class I
molecules, a natural B*2705 ligand with Ser1, the influenza
nucleoprotein epitope SRYWAIRTR (36), and its Na-
acetylated analogue were tested in an epitope estabilization
assay using B*2705–RMA-S cells. As shown in Fig. 6, the
relative binding of the N-acetylated peptide (1:5) was simi-
lar as for the HLA-B39 ligand. This result indicates that the
effect of Na-acetylation on peptide binding is similar for at
least two HLA-B allotypes.
Discussion
This study provides the first demonstration that an Na-
acetylated peptide from an endogenous cell protein is a nat-
ural HLA class I ligand. This finding challenges the current
paradigm that a free NH2 terminus is an essential feature for
natural ligands of classical class I–bound peptides.
Various posttranslational modifications have been re-
ported among natural MHC class I ligands, including deam-
idation (37), cysteine modification (38), and glycosylation
(39). However, these modifications do not affect the NH2
terminus of the peptide or otherwise alter sequence-inde-
pendent MHC–peptide interactions. Other naturally oc-
curring modifications also not affecting the peptidic NH2
terminus, such as phosphorylation, are compatible with
class I binding (40), but to our knowledge, no natural
phosphorylated class I ligands have been reported. The pos-
sibility that Na-acetylation might have occurred during
peptide purification is ruled out because it requires different
and more drastic chemical treatments than those used for
isolation of class I ligands. Moreover, multiple peptides
with unblocked NH2-terminal Ser or other residues have
been sequenced in our laboratory after using the same iso-
lation procedure (23, 41).
Three issues are raised by our results: (a) the mode of in-
teraction of N-acetylated ligands with the class I molecule;
(b) the mechanism by which such ligands might be pro-
cessed in vivo; and (c) the biological significance of class
I–mediated presentation of Na-acetylated peptides.
The first issue can be definitively addressed only by x-ray
crystallography. However, an attempt was made here to
distinguish between two alternative possibilities. In the first
one, predicted by molecular modeling (data not shown),
the P1 side chain would be accommodated in the A pocket
with the acetyl group directed outwards. This binding
mode would be expected to be strongly influenced by the
size and polarity of the P1 side chain. A second alternative
would be that the acetyl moiety is located inside the A
pocket whereas the P1 side chain points towards solvent.
Presumably, this binding mode should be less sensitive to
the nature of the P1 side chain. Our results showing that
even a significant increase in the size and hydrophobicity of
the P1 residue had only a limited influence on binding of
the N-acetylated analogue do not support the first alterna-
tive and are more compatible with the second one. How-
ever, other possibilities cannot be ruled out. For instance, if
the acetylated P1 residue is Ser or another small one, the
side chain might bind in the A pocket, and alternative
binding modes might only be adopted if the side chain is
too big. Finally, neither the P1 side chain nor the acetyl
moiety might bind in the A pocket. The cavity created in
pocket A might then be filled by a water molecule hydro-
gen bonded to Tyr7 and Tyr171, as seen in the x-ray struc-
Figure 6. Binding of a natural
B*2705 ligand upon Na-acetyla-
tion. Epitope stabilization assay
showing the expression of
B*2705 on the surface of RMA-S
transfectant cells. B*2705-asso-
ciated fluorescence at various
peptide concentrations was mea-
sured with the ME1 mAb (de-
scribed in Materials and Meth-
ods). Data are means 6 SD of
three independent experiments.
The peptides tested were the
B*2705-restricted influenza nu-
cleoprotein epitope SRY-
WAIRTR (C50: 3 mM) and its
acetylated analogue Nac-SRY-
WAIRTR (EC50: 15 mM; rela-
tive binding 1:5). The AHDE-
TEFYL peptide was used as
negative control.2090 An Na-acetylated Ligand of Class Ia HLA Antigens
ture of HLA-A*0201 in complex with a peptide for which
the free amino group was replaced by a methyl moiety
(11).
In spite of its presence in vivo, NAc-SHVAVENAL
bound in vitro z10-fold less efficiently than other natural
ligands. This might be due to the fact that the epitope sta-
bilization assay used in this study is significantly influenced
by the association rate of the peptide, whereas binding in
vivo depends on the stability of the MHC–peptide com-
plex. Thus, although the Na-acetylated ligand is suffi-
ciently stable for binding in vivo, its association rate at the
cell surface might be lower than for its counterpart with
free NH2 terminus. In vitro assays, including our epitope
stabilization assay, do not reflect peptide binding as it oc-
curs in vivo. In particular, the kinetics of MHC–class I
peptide association may be strongly influenced in vivo by
the mechanisms of assisted loading involving transporter as-
sociated with antigen processing–tapasin–MHC protein
complexes.
The interaction of Na-acetylated peptides with a classi-
cal class I protein differs significantly from the nonclassical
class I molecule H2-M3 associated to an N-formyl peptide
(19). H2-M3 presents N-formylated peptides from pro-
karyotic and mitochondrial proteins to CD81 T cells (18,
20). It can also bind nonformylated peptides, but with a
restricted specificity for Gly at P1 (42). This unusual bind-
ing motif is explained by several amino acid changes
(Trp167Leu, Tyr171Phe) that dramatically reduce the size
of pocket A and shift the P1 side chain into pocket B (19).
Another major difference of H2-M3 with classical class I
molecules is the presence of a positively charged His at po-
sition 9 that interacts with the formyl oxygen atom. H2-
M3 does not bind Na-acetylated peptides (16). Conse-
quently, binding of N-formylated peptides by H2-M3 is
very strongly favored over unblocked peptides. In contrast,
for the Na-acetylated peptide bound to a classical class I
protein described in this study, pocket A is composed of
consensus amino acids, and binding is less efficient than for
a counterpart with free NH2 terminus. The similar effect of
Na-acetylation on binding of peptide analogues with Thr1
or Ala1 suggests that acetylation of some P1 residues other
than Ser might be tolerated among natural class I ligands.
In addition, the fact that the effect of N-acetylation of Ser1
on binding to B*2705 was similar as in HLA-B39 suggests
that other MHC class I molecules besides HLA-B39 might
also bind Na-acetylated peptides.
Processing of the NAc-SHVAVENAL ligand was ap-
proached in this study by analyzing its generation from a
precursor substrate by the 20S proteasome. The high yield
of the natural ligand in vitro demonstrates that in the se-
quence context of its parental protein, a blocked NH2 ter-
minus does not impair cleavage at the precise COOH-ter-
minal residue of the natural ligand by the 20S proteasome.
This experiment does not necessarily reproduce the mech-
anism by which this ligand is processed in vivo, as much
protein breakdown in the cytosol occurs through the ac-
tion of the 26S proteasome on ubiquitinated proteins (43).
Na-acetylated proteins are degraded via the ubiquitin sys-
tem without removal of the blocked NH2 terminus (44–
47). Therefore, it is likely that NAc-SHVAVENAL is gen-
erated in vivo by an ubiquitin-dependent mechanism.
However, the cleavage pattern and high yield of the natural
ligand observed with the 20S proteasome in vitro strongly
suggest that it is directly generated by the proteasome also
in vivo.
What is the possible biological significance of class I–medi-
ated presentation of N-acetylated peptides? Na-acetyla-
tion is a common modification of eucariotic proteins, and
also occurs in viral and bacterial proteins. Although many
NH2-terminal residues can be acetylated in vivo, Ser is the
most frequent one, occurring in z40% of the Na-acety-
lated proteins (22). As shown in our study, an Na-acety-
lated peptide with appropriate size for MHC class I binding
can be generated by proteasomal cleavage with high yield.
Thus, Na-acetylated peptides with the size of class I ligands
(8–11 amino acids) might be common breakdown products
of eucariotic cell proteins.
It is generally assumed that a major mechanism of immu-
nological tolerance against self-proteins is achieved through
negative selection of autoreactive T cell precursors. Be-
cause MHC polymorphism modulates peptide specificity, a
given MHC allelic product is able to bind a limited number
of peptide ligands among those produced during the meta-
bolic breakdown of a given endogenous protein. It is likely
that not all of these peptides are equally immunogenic or
tolerogenic. This is clear, for example, in self-restricted T
cell responses against viral antigens. For a given restriction
element, these responses are usually directed against one of
very few immunodominant peptides from given viral pro-
tein (48). Because of the likely limitation in the number of
immunogenic and/or tolerogenic self-peptides from an en-
dogenous protein that can be presented by a particular class
I allotype, the capacity of class I molecules to bind Na-
acetylated peptides might contribute to enlarge the spec-
trum of self-antigens for negative selection of autoreactive
T cell repertoires.
On the basis of known MHC class I ligands, it may
be argued that Na-acetylated peptides are rare in class
I–bound peptide pools. However, it should be noted that
these ligands escape detection by classical Edman se-
quencing, and only a very small fraction of the natural class
I–bound peptide repertoires have yet been sequenced by
MS. For this reason, the presence of putative Na-acety-
lated natural ligands of MHC class I proteins might have
been underestimated.
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